Aktie A3D495 CANNARA BIOTECH INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Cannara Biotech Inc.

Aktien

A3D495

CA13765U2002

LOVE

Markt geschlossen - Toronto S.E.
Andere Börsenplätze
 18:28:38 26.04.2024 		% 5 Tage % 1. Jan.
0,84 CAD -1,18 % Intraday Chart für Cannara Biotech Inc. +2,44 % +1,20 %
29.01. Cannara Biotech Inc. meldet Ergebnis für das erste Quartal bis zum 30. November 2023 CI
2023 Cannara Biotech Inc. meldet Ergebnis für das am 31. August 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Cannara Biotech CFO Nicholas Sosiak: Unveiling Success Strategies and Future Plans
Cannara Biotech Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023
Cannara Biotech to Host Investor Webcast on Thursday December 14th, 2023
Cannara Biotech Inc. Reports Earnings Results for the Full Year Ended August 31, 2023
Cannara Biotech's Fiscal Q4 Profit, Revenue Grows; Up 9.4%
Cannara Biotech Inc. Reports Earnings Results for the Fourth Quarter Ended August 31, 2023
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.
Cannara Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023
Cannara Biotech Inc. Reports Record Q3 2023 Financial Results with Net Revenues of $15.9 Million and Net Income of $2.9 million
Cannara Biotech Inc Announces Participation in the LD Micro Invitational XIII
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.
Cannara Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023
Cannara Biotech Down Near 8% As Enters into an Automatic Share Purchase Plan
Cannara Biotech Inc. Enters into an Automatic Share Purchase Plan
Cannara biotech inc. Announces results of annual shareholder meeting and conversion into equity of a $5m convertible debenture at $0.18 cent per common share
Cannara Biotech Converts CA$5 Million Debenture, Plus Interest, into Nearly 30 Million Shares for Olymbec Investments
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.
Cannara Biotech Inc. Reports Earnings Results for the First Quarter Ended November 30, 2022
Cannara Announces Proposed Share Consolidation
Cannara Biotech Reports Normal Course Issuer Bid for Common Shares
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3D495 Aktie
  4. Nachrichten Cannara Biotech Inc.
  5. Andere Sprachen